Literature DB >> 22212863

Targeting stroma to treat cancers.

Boris Engels1, Donald A Rowley, Hans Schreiber.   

Abstract

All cancers depend on stroma for support of growth. Leukemias, solid tumors, cancer cells causing effusions, metastases as well as micro-disseminated cancer cells release factors that stimulate stromal cells, which in turn produce ligands that stimulate cancer cells. Therefore, elimination of stromal support by destroying the stromal cells or by inhibiting feedback stimulation of cancer growth is in the focus of many evolving therapies. A stringent evaluation of the efficacy of stromal targeting requires testing in animal models. Most current studies emphasize the successes of stromal targeting rather than deciphering its limitations. Here we show that many of the stromal targeting approaches, while often reducing tumor growth rates, are rarely curative. Therefore, we will also discuss conditions where stromal targeting can eradicate large established tumors. Finally, we will examine still unanswered questions of this promising and exciting area of cancer research. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22212863      PMCID: PMC3321387          DOI: 10.1016/j.semcancer.2011.12.008

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  166 in total

1.  Origin of fibroblasts in experimental healing wounds: autoradiographic studies using tritiated thymidine.

Authors:  R A MACDONALD
Journal:  Surgery       Date:  1959-08       Impact factor: 3.982

2.  What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, and fibrosis.

Authors:  Robert M Strieter
Journal:  Proc Am Thorac Soc       Date:  2008-04-15

Review 3.  Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation.

Authors:  R S Smith; T J Smith; T M Blieden; R P Phipps
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

Review 4.  The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter.

Authors:  M D Sternlicht; M J Bissell; Z Werb
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

5.  Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL.

Authors:  Pratima Sinha; Olesya Chornoguz; Virginia K Clements; Konstantin A Artemenko; Roman A Zubarev; Suzanne Ostrand-Rosenberg
Journal:  Blood       Date:  2011-03-30       Impact factor: 22.113

6.  MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells.

Authors:  Saho Utsugi-Kobukai; Haruka Fujimaki; Chie Hotta; Masatoshi Nakazawa; Mutsuhiko Minami
Journal:  Immunol Lett       Date:  2003-10-31       Impact factor: 3.685

7.  High proliferation of granulocyte-macrophage progenitors in tumor-bearing mice.

Authors:  L Balducci; C Hardy
Journal:  Cancer Res       Date:  1983-10       Impact factor: 12.701

8.  Effect of serum deprivation on constitutive production of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in lung cancer cells.

Authors:  Yoshiki Uemura; Makoto Kobayashi; Hideshi Nakata; Ryoji Harada; Tetsuya Kubota; Hirokuni Taguchi
Journal:  Int J Cancer       Date:  2004-05-10       Impact factor: 7.396

9.  Bystander elimination of antigen loss variants in established tumors.

Authors:  Michael T Spiotto; Donald A Rowley; Hans Schreiber
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

10.  Wound healing and collagen formation. VI. The origin of the wound fibroblast studied in parabiosis.

Authors:  R Ross; N B Everett; R Tyler
Journal:  J Cell Biol       Date:  1970-03       Impact factor: 10.539

View more
  34 in total

1.  The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer.

Authors:  J H Park; C H Richards; D C McMillan; P G Horgan; C S D Roxburgh
Journal:  Ann Oncol       Date:  2014-01-23       Impact factor: 32.976

Review 2.  Human cancer growth and therapy in immunodeficient mouse models.

Authors:  Leonard D Shultz; Neal Goodwin; Fumihiko Ishikawa; Vishnu Hosur; Bonnie L Lyons; Dale L Greiner
Journal:  Cold Spring Harb Protoc       Date:  2014-07-01

3.  Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.

Authors:  Andrew D Rhim; Paul E Oberstein; Dafydd H Thomas; Emily T Mirek; Carmine F Palermo; Stephen A Sastra; Erin N Dekleva; Tyler Saunders; Claudia P Becerra; Ian W Tattersall; C Benedikt Westphalen; Jan Kitajewski; Maite G Fernandez-Barrena; Martin E Fernandez-Zapico; Christine Iacobuzio-Donahue; Kenneth P Olive; Ben Z Stanger
Journal:  Cancer Cell       Date:  2014-05-22       Impact factor: 31.743

Review 4.  Adoptive immunotherapy for cancer: harnessing the T cell response.

Authors:  Nicholas P Restifo; Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

5.  Targeting Brain-Adaptive Cancer Stem Cells Prohibits Brain Metastatic Colonization of Triple-Negative Breast Cancer.

Authors:  Ding Ren; Xiaoping Zhu; Ren Kong; Zhen Zhao; Jianting Sheng; Jiang Wang; Xiaoyun Xu; Jiyong Liu; Kemi Cui; Xiang H-F Zhang; Hong Zhao; Stephen T C Wong
Journal:  Cancer Res       Date:  2018-03-22       Impact factor: 12.701

6.  Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.

Authors:  Joachim C Mertens; Christian D Fingas; John D Christensen; Rory L Smoot; Steven F Bronk; Nathan W Werneburg; Michael P Gustafson; Allan B Dietz; Lewis R Roberts; Alphonse E Sirica; Gregory J Gores
Journal:  Cancer Res       Date:  2012-12-05       Impact factor: 12.701

7.  Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.

Authors:  Anat Globerson-Levin; Tova Waks; Zelig Eshhar
Journal:  Mol Ther       Date:  2014-02-27       Impact factor: 11.454

8.  Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow.

Authors:  T Matthes; T McKee; I Dunand-Sauthier; B Manfroi; S Park; J Passweg; B Huard
Journal:  Leukemia       Date:  2015-03-10       Impact factor: 11.528

9.  A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control.

Authors:  Jennifer D Stone; Daniel T Harris; Carolina M Soto; Adam S Chervin; David H Aggen; Edward J Roy; David M Kranz
Journal:  Cancer Immunol Immunother       Date:  2014-08-01       Impact factor: 6.968

Review 10.  Deciphering and reversing tumor immune suppression.

Authors:  Greg T Motz; George Coukos
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.